Responses of killer cells in head and neck cancer patients
- 1 May 1990
- journal article
- research article
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 247 (3) , 176-181
- https://doi.org/10.1007/bf00175973
Abstract
The immunological functions of 60 patients with head and neck cancers were evaluated using in vitro natural killer cell (NK) activity, lymphokine activated killer cells (LAK) and OK-432 activated killer cells, as well as by in vivo purified protein derivative (PPD) and Su-PS skin tests. There were signifcant differences of the above three activities between stage I cancer patients and stage III and/or IV. The PPD skin test corresponded significantly to LAK activity, while Su-PS corresponded significantly to OK-432 activated killer cell activity. Responses to interleukin-2 and OK-432 of stage IV patients with head and neck cancers were different from those of stage IV with gastrointestinal cancer. These in vitro assays were very useful for the evaluation of immunological function in head and neck cancer patients, especially before any biological response modifying treatment.Keywords
This publication has 25 references indexed in Scilit:
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Intrapleural administration of OK432 in cancer patients: Augmentation of autologous tumor killing activity of tumor-associated large granular lymphocytesCancer Immunology, Immunotherapy, 1984
- Peripheral k-lymphocyte population in head and neck cancerCancer, 1984
- Clinical value of immunotherapy for lung cancer by the streptococcal preparation OK-432Cancer, 1984
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982
- Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.The Journal of Experimental Medicine, 1982
- Reduction of suppressor cells in cancer patients treated with OK-432 immunotherapyInternational Journal of Cancer, 1980
- Comparison of immune derangements in patients with different malignanciesCancer, 1980
- Clinical studies on cell-mediated immunity in patients with malignant disease I. Effect of immunotherapy with OK-432 on lymphocyte subpopulation and phytomitogen responsivenessin vitroCancer, 1980
- Spontaneous human lymphocyte‐mediated cytotoxicity againts tumour target cells. I. The effect of malignant diseaseInternational Journal of Cancer, 1976